NCT05962333View on ClinicalTrials.gov

Effect and Safety MABs Administration m.3243A>G Mutation Carriers

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

August 1, 2024

Study Completion Date

February 1, 2025

Conditions
Mitochondrial Myopathies
Interventions
BIOLOGICAL

Intra-arterial delivery of autologous MABs

three times intra-arterial administration of autologous mesoangioblasts in biceps brachii of the left arm at 4-6 week interval

Trial Locations (1)

6229ER

RECRUITING

Maastricht University Medical Center, Maastricht

All Listed Sponsors
lead

Maastricht University

OTHER